CytomX Therapeutics Inc (CTMX) — Cash Flow-to-Debt Ratio
CytomX Therapeutics Inc (CTMX) has a Cash Flow-to-Debt Ratio of -0.65x as of March 2026, meaning its operating cash flow of $-25.55 Million could theoretically repay -1% of its total liabilities ($39.41 Million) in one year. Explore long-term investment intensity of CytomX Therapeutics Inc to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
CytomX Therapeutics Inc Cash Flow-to-Debt Ratio (2013–2025)
Historical debt coverage capacity for CytomX Therapeutics Inc across 13 annual periods. Also explore how large is CytomX Therapeutics Inc's balance sheet for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for CytomX Therapeutics Inc (2013–2025)
Year-by-year debt coverage analysis for CytomX Therapeutics Inc. For market capitalisation and broader financial context, see CTMX market cap overview.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -1.44x | $-75.59 Million | $52.56 Million | ▼ -101.8% |
| 2024 | -0.71x | $-86.23 Million | $120.99 Million | ▼ -217.0% |
| 2023 | -0.22x | $-56.03 Million | $249.24 Million | ▲ +29.7% |
| 2022 | -0.32x | $-110.79 Million | $346.64 Million | ▲ +32.9% |
| 2021 | -0.48x | $-119.03 Million | $250.03 Million | ▼ -3417.1% |
| 2020 | 0.01x | $5.26 Million | $366.44 Million | ▲ +103.0% |
| 2019 | -0.48x | $-140.48 Million | $290.17 Million | ▼ -109.1% |
| 2018 | -0.23x | $-75.52 Million | $326.23 Million | ▼ -144.5% |
| 2017 | 0.52x | $170.37 Million | $327.75 Million | ▲ +3186.5% |
| 2016 | -0.02x | $-2.03 Million | $120.65 Million | ▲ +95.6% |
| 2015 | -0.39x | $-27.41 Million | $71.15 Million | ▼ -283.7% |
| 2014 | 0.21x | $31.80 Million | $151.60 Million | ▲ +253.1% |
| 2013 | -0.14x | $-8.01 Million | $58.46 Million | — |